Skip to main content
. 2020 Oct 29;2020:5162541. doi: 10.1155/2020/5162541

Table 1.

Clinical and laboratory parameters of PBC patients and healthy controls.

Feature Healthy controls (n = 10) Non-cirrhotic PBC patients (n = 26) Cirrhotic PBC patients (n = 20)
Age (years) 53.20 ± 4.13 52.12 ± 2.11 53.95 ± 2.63
Gender (male) 4 3 7
Weight change (kg) 0.300 ± 0.44 −0.962 ± 0.51 −1.50 ± 0.43#
Weight change (%) 0.47% ± 0.71% −1.49% ± 0.77% −2.71% ± 0.74%#
>5% within past 6 months 0 2 4
BMI (kg/m2) 23.27 ± 2.51 21.39 ± 2.09 19.82 ± 2.12#
Low BMI (<18.5 if <70 years) 0 2 6
CRP (mg/L) 3.37 ± 0.49 8.89 ± 1.87 15.99 ± 1.75
CRP > 5 mg/L 0 13 12
Malnutrition (n, %) 0 4 (15.38%) 9 (45%)#
GDF15 (pg/mL) 656.58 ± 146.13 3037.41 ± 568.91 4926.44 ± 662.84#
ALT (U/L) 15.80 ± 1.98 113.00 ± 17.37 85.85 ± 15.27
AST (U/L) 21.80 ± 1.29 114.12 ± 15.64 102.10 ± 14.09
TBIL (μmol/L) 8.56 ± 1.34 59.85 ± 12.49 95.69 ± 18.58
DBIL (μmol/L) 2.91 ± 0.56 43.71 ± 10.78 69.87 ± 14.58
GGT (U/L) 25.80 ± 4.62 474.08 ± 84.86 309.60 ± 71.96
ALP (U/L) 60.30 ± 5.66 308.08 ± 41.13 269.95 ± 25.71
TBA (μmol/L) 3.27 ± 0.34 81.18 ± 16.80 132.54 ± 19.57#
ALB (g/L) 43.98 ± 0.52 38.39 ± 0.85 34.24 ± 1.02#
GLB (g/L) 27.13 ± 1.16 34.75 ± 1.28 35.86 ± 2.25
INR 0.95 ± 0.01 1.04 ± 0.06 1.28 ± 0.09#
MELD score N/A 5.73 ± 1.07 10.14 ± 1.47#
Mayo risk score N/A 5.53 ± 0.29 6.58 ± 0.35#
ANA positive 0 25 19
Anti-SP100 0 1 1
Anti-GP210 0 1 4
AMA positive 0 22 16
AMA-M2 positive 0 9 6

p < 0.05 compared to corresponding values in healthy controls. #p < 0.05 compared to corresponding values in non-cirrhotic PBC patients. PBC: primary biliary cholangitis; BMI: body mass index; GDF15: growth differentiation factor 15; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; TBA: total bile acids; ALB: albumin; GLB: globulin; INR: international normalized ratio; CRP: C-reactive protein; MELD score: Model for End-stage Liver Disease score.